{"nctId":"NCT01191801","briefTitle":"Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML","startDateStruct":{"date":"2010-12-17"},"conditions":["Acute Myeloid Leukemia"],"count":711,"armGroups":[{"label":"Group A: vosaroxin + cytarabine","type":"EXPERIMENTAL","interventionNames":["Drug: vosaroxin + cytarabine"]},{"label":"Group B: placebo + cytarabine","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo + cytarabine"]}],"interventions":[{"name":"vosaroxin + cytarabine","otherNames":[]},{"name":"placebo + cytarabine","otherNames":["control"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provided signed, written informed consent\n* At least 18 years of age\n* Had a diagnosis of AML according to World Health Organization (WHO) classification\n* First relapsed or refractory AML (refractory to initial induction therapy) with at least 5% blasts by bone marrow or aspirate or 1% blasts in peripheral blood with additional requirements for relapsed or refractory\n* Had an ECOG score of 0-2\n* Had adequate liver and renal function as indicated by certain laboratory values\n* Had adequate cardiac function (left ventricular ejection fraction at least 40% by multiple gated acquisition scan or ECG)\n* Nonfertile or agreed to use an adequate method of contraception until 30 days after the last treatment\n* Had any clinically significant nonhematologic toxicity after prior chemotherapy recovered to Grade 1 per NCI-CTCAE\n\nExclusion Criteria:\n\n* Had acute promyelocytic leukemia\n* Had more than 2 cycles of induction therapy for AML\n* Had completed a single cycle of treatment containing a total dose of 5 g/m2 or more of cytarabine within 90 days before randomization\n* Refractory to or relapsed within the previous 3 months after therapy with an IDAC- or HIDAC-containing regimen\n* Had received a hematopoietic stem cell transplant (HSCT) within the previous 90 days\n* Had received active immunosuppressive therapy for graft-versus-host disease (GVHD) within 2 weeks before study start\n* Had any other severe concurrent disease, or have a history of serious disease involving the heart, kidney, liver, or other organ system\n* Had evidence of central nervous system involvement of active AML\n* Had other active malignancies (including other hematologic malignancies) or been diagnosed with other malignancies within the last 12 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia\n* Had an active, uncontrolled infection\n* Had received any other investigational therapy within 14 days or not recovered from acute affects of the other investigational therapy\n* Had received prior or current hydroxyurea or medications to reduce blast count within 24 hours before randomization\n* Had received previous treatment with vosaroxin\n* Pregnant or lactating\n* Had any other medical, psychological, or social condition that may interfere with consent, study participation, or follow-up\n* Had known HIV seropositivity","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Vosaroxin + cytarabine patient survival versus placebo + cytarabine patient survival","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"6.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Remission (CR) Rate Based on Modified International Working Group (IWG) Criteria.","description":"Group A (Vosaroxin + cytarabine) patient CR as compared to Group B (placebo + cytarabine) patient CR. Complete remission (CR) is typically defined using IWG criteria as bone marrow blast count of less than 5% with adequate recovery of peripheral blood counts.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":null},{"groupId":"OG001","value":"16.3","spread":null}]}]}]},{"type":"SECONDARY","title":"All Cause Mortality","description":"Vosaroxin + cytarabine mortality versus placebo + cytarabine mortality","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"6.6","spread":null}]}]}]},{"type":"SECONDARY","title":"All Cause Mortality","description":"Vosaroxin + cytarabine mortality versus placebo + cytarabine mortality","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":null},{"groupId":"OG001","value":"19.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Overall Remission (OR) Rate Based on the IWG Response Criteria","description":"Group A patient OR compared to Group B patient OR\n\nOverall Remission includes Complete Remission (CR), Complete Remission with incomplete platelet recovery (CRp), Complete Remission with incomplete blood count recovery (CRi), and Partial Remission (PR). Complete remission means bone marrow blast count of less than 5% with adequate recovery of peripheral blood counts as typically defined by the IWG. Both CRi and CRp refer complete remission but with incomplete blood count and platelet recovery, respectively. PR, or partial remission, refers to remission in which bone marrow contains blast counts between 5 and 25 percent.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.9","spread":null},{"groupId":"OG001","value":"18.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Event Free Survival (EFS)","description":null,"paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Leukemia-Free Survival (LFS)","description":"Durability of remission (CR) assessed by LFS","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":197,"n":355},"commonTop":["Nausea","Diarrhoea","Constipation","Hypokalaemia","Febrile neutropenia"]}}}